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Abstract 
Myocarditis is one of the most common non-coronary diseases, since it is associated with many 
infectious and immune-allergic diseases, such as HIV, hepatitis, systemic bacterial and fungal 
infections. Moreover, this nosological form can be also associated with the side effects of various 
medicines. For instance, some chemotherapeutic drugs, such as trastuzumab used to treat breast 
cancer, are able to trigger the myocarditis development. Understanding of mechanisms of the 
myocarditis development under the similar drugs action, and awareness of a physician about their 
high risk will help him to avoid undesirable complications, and thereby, to increase the survival rate 
and standard of living of the world’s population. This article has incorporated all the aspects of the 
classification, etiology, pathogenesis, morphogenesis, as well as the clinical manifestations, 
diagnosis and treatment. 
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Introduction 
Myocarditis or inflammatory cardiomyopathy 
is a focal or diffuse inflammation of the heart 
muscle accompanied by an impairment of its 
functioning. It is often induced by infectious 
agents, and less often by non-infectious 
agents, herein both the cardiomyocytes and 
the interstitial tissue can be involved in the 
inflammatory process. 
In humans ongoing myocardial inflammation 
may result in dilated cardiomyopathy, 
restrictive cardiomyopathy or acute left 
ventricular failure without dilation - 
myocarditis. 
Myocarditis is considered to be a disease of 
young people, although it can develop in any 
period of life. The average age of the patients 
varies from 30 to 40 years, and women are 
getting affected with myocarditis somewhat 
more often comparably to men, but despite 
this, men often have severe forms of the 
disease manifestation. 
Clinical course is usually self-limiting. The 
major long-term complication is dilated 
cardiomyopathy with heart failure. 
According to Roitberg and Strutinski (2017, 
p.809) high clinical suspicion is necessary for 
diagnosing myocarditis and 2/3 of the patients 
develop spontaneous recovery while another 
1/3 requires aggressive treatment. 
Clinical result depends on virulence of active 
agent, immune response and ability to reverse 
the damage. 
Depending on the etiological factor all 
myocardites can be divided into two large 
groups, namely: 
1. Primary/Idiopathic/Giant 
Cell/Isolated/Abramov-Fiedler’s 
myocarditis - myocarditis of unknown 
etiology. This diagnosis is made only 
after unsuccessful, but long-term and 
competent attempts in the specific 
pathogen identification. 
2. Secondary/Infectious/Common - this 
diagnosis is made when a definite 
pathological agent is found that has  
triggered the entire cascade of 
pathological reactions. 
 
 
PRIMARY MYOCARDITIS  
Primary or the giant cell myocarditis is a 
severe non-specific myocardial inflammation 
that occurs with the development of 
cardiomegaly, heart failure, significant 
disorders of rhythm and conductivity, as well 
as the thromboembolic syndrome evolving.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Classification 
On the basis of histological signs there are 
four types of idiopathic myocarditis 
distinguished: dystrophic, inflammatory-
infiltrative, mixed and vascular. 
In the dystrophic (destructive) type of the 
giant cell myocarditis, the processes of 
hydropic dystrophy of the muscle fibers with 
their subsequent total death and the affected 
area myolysis predominate. 
According to Sarkisov and Hitrov (1997, 
p.423) the inflammatory-infiltrative type of 
idiopathic myocarditis is characterized by the 
interstitial tissue oedema and its infiltration 
with various cellular elements.
23
 In the acute 
stage the polymorphonuclear neutrophilic 
granulocytes or eosinophilic leukocytes are 
found in large quantities in the exudates. In 
case of long-term disease, the plasma or 
multinucleated giant cells predominate in the 
infiltrate. The mixed type of the giant cell 
myocarditis is a combination of the 
dystrophic and inflammatory-infiltrative  
Figure 1.Giant cell myocarditis. H&E staining (40x). http://heartpathology.com 
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variants. The vascular type of the giant cell 
myocarditis occurs with a primary lesion of 
small branches of the coronary arteries. 
According to Strukov, Serov and Paukov 
(2015, pp. 368) as per duration the giant cell 
myocarditis is classified in to acute (2-8 
weeks), subacute (from 3 to 18 months), 
recurrent chronic (lasts for years). 
The latent form of idiopathic myocarditis 
occurring without clear symptoms is less 
common. Asystolic, arrhythmic, 
thromboembolic, pseudo-coronary and mixed 
forms of Abramov-Fiedler’s myocarditis are 
distinguished according to clinical signs. 
 
• Etiology 
The word “idiopathic” indicates an unclear 
etiology of the disease. A number of 
researchers (Sarkisov, Abrikosov, Rapoport 
and others) substantiated the autoimmune 
nature and the auto-allergic mechanism of 
development of the giant cell myocarditis. 
Often it is preceded by serum sickness, 
eczema, and drug allergies. In recent years, 
the role of other possible triggering factors 
that are capable to induce the idiopathic 
myocarditis mechanisms, in particular, the 
viral infections and autoimmune reactions 
have been discussed. 
The viral genesis hypothesis of the giant cell 
myocarditis is approved by statistical data: in 
patients who have experienced acute viral 
myocarditis, the chronic idiopathic 
myocarditis occurs in 4-9% of cases against 
0.005% over the general population. There is 
an accepted point of view that the giant cell 
myocarditis is an extreme variant of the 
infectious-allergic myocarditis. 
Approximately in 20% of patients the giant 
cell myocarditis develops on the background 
of autoimmune diseases: Takayasu’s disease, 
Hashimoto's thyroiditis, Crohn’s disease. The 
immune-pathological mechanism of 
inflammation is indicated by identification of 
the antibodies to myocardium and by the 
cellular cytotoxicity. 
The typical morphological signs of the giant 
cell myocarditis are the following: isolated 
heart damage, a combination of extensive  
 
dystrophy, infiltrative-inflammatory 
myocardial changes with common 
cardiosclerosis, intracardiac thrombosis and 
embolism of the systemic circulation arteries. 
According to Palcev, Kakturski and Zairatian 
(2011, p.464) macroscopically, the giant cell 
myocarditis reveals flabbiness of the cardiac 
walls and stretching of the heart cavities, the 
presence of parietal blood clots on a section - 
variegation of the myocardium staining. 
Microscopic examination draws attention to 
hypertrophy of the muscular fibers (to a 
greater extent, papillary muscles and 
subendocardial layers of the myocardium), 
extensive fields of myolysis with the 
connective muscle tissue replacement, 
presence of the signs of coronaritis, such as 
the inflammatory infiltrates along the small 
branches of coronary vessels. 
 
• Diagnostics of idiopathic giant cell 
myocarditis 
There is no specific diagnosis. The diagnosis 
is made only by the method of exclusion of 
the possible microorganisms’ activity with the 
minimal cardiotropic action. 
 
•  Treatment of the giant cell myocarditis 
The etiotropic therapy of the giant cell 
myocarditis has not been developed. The 
symptomatic treatment of heart failure, 
arrhythmias, prevention of thromboembolic 
complications is conducted. For this purpose 
the bed rest regimen, diet therapy, medication 
(nitrates, cardiac glycosides, diuretics, ACE 
inhibitors, beta-blockers, aldosterone 
antagonists, anticoagulants) are prescribed. 
The anti-inflammatory therapy includes the 
non-steroidal anti-inflammatory drugs 
prescription (e.g. indomethacin, diclofenac); 
in severe forms of the giant cell myocarditis 
with the immune reactions hyperactivity 
glucocorticoids are used; in those which are 
with the allergic background, the 
desensibilizing agents are applied. 
Additionally, the drugs of metabolic action 
(e.g. trimetazitine, cocarboxylase, inosine, 
potassium orotate, vitamins) are used. For the   
giant-cell myocarditis the heart 
transplantation is indicated. 
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SECONDARY MYOCARDITIS  
Secondary/infectious myocarditis develops as 
a result of the destructive effects of various 
pathological agents, that is, it is a 
manifestation and often a complication of 
another disease, for example, the Lyme 
disease, the end-stage of AIDS or being as a 
result athracycline induced cardiotoxicity. 
Fore-example, in HIV-infected people with 
extremely low immune status the evidence of 
myocarditis is very high due to secondary 
opportunistic infection, and also able to be 
associated with antiviral drugs taking , and 
Kaposi’s sarcoma. 
 
• Classification  
1. As per etiology: 
-  infectious, 
-  non-infectious. 
2.  As per pathogenesis: 
-  infectious, 
-  allergic, 
-  of the mixed character. 
3. As per localization: 
-  parenchymatous, 
-  interstitial. 
4. As per prevalence: 
-  focal,  
-  diffuse. 
5. As per duration: 
- acute, 
- subacute, 
- reccurent, 
- latent, 
- chronic, 
6. As per clinical durathion: 
-  infectious, 
-  pseudocoronar, 
-  decompensated, 
-  arrhythmic, 
-  subvalvular, 
-  thromboembolic, 
 
 
 
 
 
-  mixed. 
7.  As per histology examination: 
- lymphocytic; 
- eosinophilic; 
- neutrophilic; 
- granulomatous.  
8.  As per outcome: 
- with convalescence, 
- with transition from the acute form to the 
chronic one, 
- with post-myocardial cardiosclerosis with 
the development of heart failure and cardiac 
arrhythmias. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Etiology 
According to Husain (2018, pp.754-757) the 
infectious causes of myocarditis during the  
 
Figure 2. Lymphocytic myocarditis, H&E staining, 20x. http://heartpathology.com 
Figure 3. Lymphocytic myocarditis, trichrome standing, 20x. Highlights the 
cardiomyocyte necrosis. http://heartpathology.com 
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last decades have been studied in some 
details; it has been established that the disease 
is caused by a wide variety of viruses, 
microbes, rickettsiae, fungi and protozoa. It is 
proved that viruses possess the greatest 
cardiotropic properties, and the viral etiology 
of myocarditis is considered to be the most 
reasoned one. 
As a proof of the viral theory of myocarditis, 
the following arguments are cited: 
- a high incidence of myocarditis during the 
viral epidemics, 
- detection of viruses in the nasopharynx and 
feces of the patient during the first week of 
acute myocarditis; the appearance in the 
blood of an antiviral antibody titer starting 
from 2-3 weeks after the acute myocarditis 
development, 
- detection of viruses and viral agents from 
the myocardium, 
- in the myocarditis associated with viral 
infection, the inflammatory changes were 
revealed in the heart biopsy specimens. 
Myocarditis can also occur with the 
simultaneous exposure of two or more 
different infections, when one of them, as a 
rule, provides conditions for myocardial 
damage, and the other is the direct cause of it. 
Myocarditis constitutes 8.6% of the sudden 
death in young adults and 10-40% of 
idiopathic dilated cardiomyopathy cases. 
According to Braunwald’s (2018, p. 2011) it 
is more common in men considering 
ardioprotective effects of hormones in 
women, while men sex hormones have the 
inhibitory antiinflammatory effect.
 
 
- Pathomorphology: 
In myocarditis a wide range of histological 
changes in the myocardium is observed, 
which to some extent reflect the clinical 
peculiarities of the disease. In acute 
myocarditis in the macroscopic examination 
the myocardial flabbiness, focal bleeding, and 
in some other cases the development of 
microaneurysms are noted. 
In the chronic course of myocarditis 
substitutive interstitial fibrosis, hypertrophy  
 
with areas of the muscle fibers’ destruction, 
foci of interstitial infiltration with 
mononuclear cells, the presence of cords of 
granulation and fibrous tissue are detected. 
Microscopically, changes in the shape, size 
and interrelated position of myocytes are 
revealed. 
There are certain morphological criteria of 
inflammatory reaction in the myocardium, 
which include lymphohistiocytar infiltrates 
with a small number of plasma cells in the 
interstitial tissue, different grade destruction 
of muscle fibers and interstitial edema 
development, deposits of immunoglobulins 
and complement in the sarcolemma and 
interstitium with damage to the capillary 
endothelium. In more rare cases a dystrophy 
of cardiomyocytes may prevail accompanied 
by just an insignificant cellular reaction, 
which ends with myocytolysis. 
Granulomatous infiltration in the 
myocardium, most often of infectious origin, 
is observed in tuberculosis, syphilis, 
rheumatism, sarcoidosis, and Wegener's 
granulomatosis. 
Despite of diversity of the viral agents and the 
major etiology background, according to U. 
Kühl and Schultheiss (2014, p.23) the overall 
incidence of myocardial infections is 
estimated at 3-6%. 
When development of myocarditis is 
associated with tuberculosis, syphilis and 
typhoid fever, the immune component is 
especially pronounced. In most cases 
extensive lymphohistiocytic infiltration in the 
stroma of the myocardium and granulomatous 
lesions are determined. 
The associated with diphtheria and scarlet 
fever myocarditis have a particularly severe 
clinical course, which is caused by the action 
of a toxin that damages the enzymatic 
systems of cardiomyocytes, inhibits the 
protein synthesis, and also causes diffuse 
autoimmune damage to the myocardium. As a 
result of the toxic damage, histological 
examination revealed an expressed 
breakdown of myocardial fibers. At the same 
time, it remains not fully clear whether this is 
an acute infection, or whether it is an  
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autoimmune response to the toxic myocardial 
damage, responsible for the abnormalities 
emerging in the structure and function of the 
heart. 
In the pathogenesis of myocarditis an 
activation of enzymatic systems and the 
release of a large number of biologically 
active substances, such as histamine, 
serotonin, bradykinin, heparin, acetylcholine, 
etc., are quite essential. These inflammatory 
mediators lead to vascular damage of the 
microvascular bed of the striated cardiac 
muscle tissue, which in turn brings to hypoxia 
development and the hypoxia inducible factor 
(HIF) activation with a subsequent alteration 
and the small islets of myocardionecrosis 
formation. 
The specificity of the etiological factor most 
often is important during the acute stage of 
the process. Further clinical manifestations 
and the course of myocarditis are largely 
conditioned by the immune and autoimmune 
reactions practically not related to a specific 
etiological factor, as well as directly by the 
processes of inflammation-healing. 
Despite the difference of etiological factors, a 
similar morphological reaction of the 
immune-allergic inflammation develops in the 
myocardium, which could be represented by 
the following: 
• increased permeability of the vascular wall 
of the microvascular bed, 
• activation of the complement system, and 
release of biologically active substances, 
• development of hypersensitivity reactions of 
immediate and delayed types. 
 
• Pathogenesis 
Infectious agents can cause damage to 
cardiomyocytes by one of four known 
mechanisms: 
1. direct myocardiocytolytic effect due to the 
myocardial invasion and pathogen replication, 
2. cellular damage by circulating of toxins 
during the systemic infection, 
3. non-specific cellular damage due to the 
cellular inflammation, 
 
 
4. cellular damage due to the production of 
various factors by the specific cells or the 
humoral immune system in response to an 
affecting agent or caused by neoantigens’ 
action. 
The latter mechanism, triggered by an 
antigen, thereafter is supported by the newly 
produced autoantigens or the myocytes’ 
antigens that are similar to initiating antigens. 
This is a mechanism of ongoing immune 
stimulation in response to damage. 
Apparently, the described mechanism is a 
common variant of the myocardial damage, 
and its activity persists for a long time after 
the removal of the initiating agent. Obviously, 
the viral myocardites develop in this way. The 
disease develops when a cardiotropic strain of 
the virus penetrates into the myocardium. It 
has been established that the cardiovirulence 
of the virus can be encoded by the process, 
the first fragments (VP2 or the capsid protein 
1B and CVB3 5’NTR) are captured, a 
mutation or removal of which leads to a 
sharpweakening of the virus cardiovirulence. 
There is a concept of the staged duration of 
myocarditis: the first stage (viremia) is short, 
lasts from several hours to several days. 
Being penetrated into the myocardium, the 
virus is fixed on the superficial receptors of 
myocytes, and then it passes into the nucleus 
of the cell. At the same time, the protective 
mechanisms are activated and the release of 
interferon increases. Virus-neutralizing IgM 
antibodies are increasingly produced. 
Stimulation of the immune reactions occurs 
by activating the co-receptors of tyrosine 
kinase p56M, associated with DAF(decay-
accelerating factor) by the classical cell-
mediated way (activation of macrophages and 
T-lymphocytes). T-lymphocytes (especially 
the CD59 subpopulation - the cytolytic T 
lymphocytes) are capable to find the DAF- 
and CAR-molecules (Coxackie adenovirus 
receptor) of the infected cells and destroy 
them with the help of produced cytokines or 
through the porphyrin-mediated cytolysis. 
The anti-cardiac antibodies (IgG) produced 
by B-lymphocytes CD22 appear in the blood,  
which in the presence of T-lymphocytes or a 
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Table 1. Classification of the causative agents of myocarditis by Avagimyan: 
Type of agents  Representative 
Infection Viral agents and disorders 
(virus positive myocardit) 
Adenovirus, Arbovirus, 
Coxsackievirus B, 
Cytomegalovirus, Dengue 
virus, ECHO virus, Chicken 
pox viruses, Epstein-Barr virus, 
Flavoviruses, Hepatit C, 
Herpes virus type VI, Human 
immunodeficiency virus, 
Influenza A and B virus, 
Measles virus, Mumps, 
Parvovirus B19, Poliomyelitis, 
Rabies, Rubella, Rubeola, 
Varicella, Variola, Yellow 
fever. 
Bacterial agents and disorder  Brucella, Chlamydia, Cholera, 
Clostridia, Diphtheria, 
Hemophilus, Legionella, 
Meningococcus, Mycoplasma, 
Neisseria gonorrhoea, 
Pneumococcus, Psittacosis, 
Salmonella, Staphylococcus, 
Streptococcus, Tetanus, 
Tuberculosis, Tularaemia. 
Spirochetal disorders, such as 
Leptospirosis, Lyme disease, 
Relapsing fever, Syphilis. 
Mycotic agents and disorders  Actinomyces, Aspergilius, 
Blastomyces, Candida, 
Coccidiodomycosis, 
Cryptococcosis, Histoplasma, 
Mucormycosis, Nocardia, 
Sporotrichosis. 
Protozoal and helminthic 
agents and disease   
African sleeping sickness, 
Amebiasis, Chagas’ disease, 
Leishmaniasis, Malaria, 
Toxoplasmosis, Trichinosis, 
Ascariasis, Trichinosis, 
Echinococcosis, 
Shystomatosis, Filariasis, 
Paragonimiasis and also 
Strongyloideus. 
Rickettsial diseases  Q fever, Rocky Mountain 
spotted fever, typhus. 
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Type of agents  Representative 
Immuno-allergic and 
infectious-allergic reactions 
Cardiotoxins Anthracyclines, sulfonamides, 
methyldopa. 
Some regimens of highly 
active antiretroviral therapy 
(for example, zidovudine 
regimens), as well as other 
drugs that require long-term, 
and sometimes lifelong 
treatment (for example, long-
term administration of shock 
doses of some antibiotics, in 
particular anti-tuberculosis 
drugs. 
And also, alcohol, arsenic, 
carbon monoxide, 
catecholamines, cocaine, heavy 
metals. 
Systematic disorders  Vasculitis, Celiac disease, 
Connective tissue disorders, 
Hypereosinophilia, Kawasaki 
disease, Sarcoidosis, Wegener 
granulomatosis and systematic 
lupus erythematous, 
Hashimoto's thyroiditis and 
Crohn’s disease. 
Post viral  Occur as a rule with a 
weakened immunity. 
Post-streptococcal  Emerging against the 
background of rheumatic fever. 
Toxic-allergic reaction  Become as a result in the long-term current chronic alcoholism, 
drug addiction, thyrotoxicosis and uremia. 
 
complement have a significant cytolytic 
effect. In 10-14 days after the onset of the 
disease the viruses in the myocardium are not 
detected, the inflammation gradually 
subsides. According with Fung et al (2016, p. 
459-514) the persistence of viral DNA/RNA 
can be determined even within 90 days after 
inoculation.  
In the long-term presence of the antigen in the 
myocardium or with defects in the immune 
system, the second, autoimmune stage is 
activated. At this stage the specificity of the 
disease is getting lost. The acute myocarditis 
transition to an autoimmune 
 
 
disease is accompanied by an increase in the 
production of anti-cardiac antibodies, increase  
in the cellular immune response, the 
manifestation of circulating immune 
complexes in the blood and their fixation in 
the myocardium, which affects more the heart 
muscle. 
Moreover, the acute inflammatory response 
mediators are activated; the lysosomal 
enzymes, adhesion molecules, prostaglandins, 
kinins, serotonin, histamine, bradykinin, 
heparin, acetylcholine are released, which 
leads to the vascular damage of 
microvasculature (increased permeability,  
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edema, hemorrhages) and the myocardial 
hypoxia with the micronecrosis foci 
formation. The processes of apoptosis are 
activated. According to Baboonyan (1992, 
pp.539-540) the collagen fibers synthesis 
starts from 5-6 days of the disease and 
reaches its maximum at 10-14 days. All these 
factors exacerbate the myocardial 
dysfunction, increase the end-diastolic 
volume of the left ventricle, and increase the 
pressure in the left atrium and pulmonary 
veins, thereby forming the signs of heart 
failure. In a favorable course of myocarditis 
recovery gradually occurs: interstitial edema 
and the cellular infiltration decrease, fibrous 
tissue areas are getting formed. 
In case of unfavorable events the disease 
passes into the third stage of its development 
– the chronic inflammation with the gradual 
formation of cardiosclerosis, cardiomegaly 
and exacerbation of the heart failure. 
As a result of the chronic inflammation in the 
heart muscle a number of characteristic 
processes occur that determine the clinical 
pattern and outcome of the disease, which 
consists of the following: 
1. inflammatory cellular infiltrate 
accumulation, formation stoma’s edema, 
necrosis, dystrophy, development of the 
fibrous tissue, 
2. decrease in myocardial contractility and 
weakening of the left ventricular systolic 
function often with the development of 
dilatation of the heart chambers. Moreover, 
recently Kuhl and Schultheiss (2014, pp. 38-
39) showed that persistence of viral genome 
in biopsy may predict deterioration in 
ventricular function, 
3. diastolic dysfunction of the left ventricle, 
resulting in increased rigidity of the heart 
muscle and inhibition of the process of active 
relaxation, 
4. stagnation in the veins of the pulmonary 
and less often of the systemic circulations, 
5. formation of electrical instability of the 
ventricular myocardium, which increases the 
risk of ventricular arrhythmias appearance, 
6. affection of the cardiac conductive system 
with the intraventricular and atrioventricular 
blockades development. 
 
Extracardiac factors which also play an 
important pathogenetic role include: 
 
-  
-  
-  
-  
-  
-  
-  
-  
-  
 
 
 
- hypoxemia due to croup, obstructive 
bronchitis, pneumonia, respiratory 
distress syndrome, neuropathic 
respiratory disorders, 
- circulatory hypoxia as a result of 
hypovolemia and reduction of the 
heart pumping function, haemic 
hypoxia, DIC-syndrome, histotoxic 
hypoxia, adrenal insufficiency, 
impairment of the heart autonomic 
innervation. 
 
• Clinical manifestation and diagnosis 
Clinical symptoms of myocarditis could 
include discomfort in chest, signs of heart 
failure, fainting, palpitations and sudden 
cardiac death. Patients with acute myocarditis 
may describe recent (recent days or weeks) 
colds with symptoms of a respiratory or 
gastrointestinal infection that precedes the 
cardiac disorders occurrence. Despite this, the 
acute myocarditis without severe symptoms is 
often not diagnosed. 
Two types of acute myocarditis are clinically 
distinguished: the acute fulminant and the 
acute non-fulminant ones. 
1. Acute fulminant myocarditis. In the acute 
fulminant myocarditis patients complain of 
an acute, spontaneous onset and a rapid 
progression of pain in the heart region 
(from several hours to several days). 
Patients report the following symptoms of 
heart failure: shortness of breath with  
Figure 4. Pathophysiology of viral myocarditis
12 
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minimal exertion and less frequently at 
rest, as well as peripheral edemas. Along 
with the left ventricle dilatation its function 
impairs until the pulmonary edema 
development occurs.                                                                                                             
Patients may require both inotropic 
medication and mechanical support for the 
left ventricle. In the future, in case of the 
subsiding acute fulminant myocarditis, the 
function of the left ventricle can 
significantly improve, and as the 
observations of such patients show, they 
even become normalized. This served as 
the basis for the hypothesis that the 
function of the left ventricle improves after 
elimination of the virus and resolution of 
myocarditis. The viral fulminant 
myocarditis is less common comparably to 
the non-fulminant form of the disease. 
2. Acute non-fulminant myocarditis is usually 
characterized by acute onset, symptoms of 
angina pectoris, elevation or depression of 
the ST segment, as well as inversion of the 
T wave on the electrocardiogram. These 
changes are accompanied by an increase in 
the activity of creatine phosphokinase of 
the MB fraction (CPK-MB) and troponin, 
which in the absence of coronary artery 
stenosis mimics myocardial infarction. The 
activity of CPK-MB and troponin is 
usually normalized within 60 hours. The 
concentration of C-reactive protein is often 
elevated. In the acute non-fulminant 
myocarditis the general systolic function is 
preserved despite the fact that regional 
contractility and diastolic dysfunction often 
develop. Moreover, pericardial effusion 
and edema of the walls can be detected in 
EchoCG. 
In the patients with viral infection, as a rule, 
non-specific complaints associated with the 
affection of many organs and systems persist, 
which are the following: 
- in the central and autonomic nervous 
systems - weakness, headache, increased 
fatigue, severe sweating, chronic diarrhea, 
mild tremor, night sweats, weakness, 
apathy, etc., 
 
 
 
- in the respiratory system organs - runny 
nose, cough, tearing, hoarseness, sore 
throat, which is worsen when swallowing, 
- muscle and joint pain - arthralgia and 
myalgia, 
- in the gastrointestinal system - anorexia, 
nausea, abdominal pain. 
The first cardinal complaints include pain in 
the region of the heart, shortness of breath, 
progressive muscle weakness, fatigue and 
impaired performance.  
The list of symptoms of includes myocarditis: 
- pain in the heart witch is one of the most 
frequent cardiac complaints of the patients 
with myocarditis. The pains are localized 
in the apex of the heart, to the left of the 
sternum and are commonly of oppressive, 
aching, piercing character. In contrast to 
angina pectoris in coronary heart disease, 
pain in myocarditis is prolonged, almost 
constant, not associated with physical 
exertion and not inhibited by nitroglycerin, 
- dyspnea on exertion and at rest is the first 
subjective symptom of the left ventricular 
heart failure developing. Dyspnea may 
increase in a horizontal position due to an 
increase in venous blood flow to the right 
heart. Such patients take a forced reclining 
position (orthopnea), 
- attacks of suffocation are observed 
relatively rarely, only in the advanced 
stages of myocarditis, due to significant 
stagnation of blood in the lungs, for 
example, in the giant-cell myocarditis. In 
case of sudden onset of asphyxiation the 
diagnosis should be differentiated from the 
pulmonary artery thromboembolism 
(PATE), 
- tachycardia associated with a decrease in 
cardiac output and compensatory activation  
- of the sympathetic component of the 
autonomic nervous system, 
- disturbance in the heart function due to a 
variety of rhythm disorders, 
- edema in the lower extremities as a 
manifestation of the left ventricular failure, 
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- pain in the right and left hypochondrium is 
associated with the hepatolienal syndrome, 
- fever is a frequent but not a mandatory sign 
of myocarditis. In acute cases it can be 
caused by both an infectious disease and 
the inflammation localized in the heart 
muscle. Absence of increased temperature 
still does not exclude an active 
inflammatory process in the heart muscle.  
In auscultation, depending on the severity of 
the disease, there is a weakening of the heart 
tones, even up to a complete deafness. 
Sometimes you can also detect the splitting of 
the 1st tone, the degree of which also 
correlates in dependence on the severity of 
the process. The pathological rhythm of 
gallop is heard. In the myocarditis with mitral 
disorders a systolic murmur is heard, and in 
the patients with marked dilatation of the left 
ventricle a diastolic murmur is heard. 
An ECG study shows not specific but 
prognostic changes in almost 100% of the 
patients. These changes are the following: 
- abnormal ST segment, 
- negative T wave, 
- blockade of the left and less often of the 
right leg of the His bundle, 
- AV blockade of the 1st and 2nd degree, 
- sinus tachycardia, rarely bradycardia, 
- extrasystoles, 
- ventricular and supraventricular 
tachycardia, 
- local, infarct-resembling changes in the Q 
wave. ECG dynamics is significant in 
diagnosis and  
treatment. 
Since there are no specific echocardiographic 
features of myocarditis, an ultrasound 
examination of the heart is carried out mainly 
in order to determine the size of the left 
ventricle and the left atrium, as well as to   
 
 
dynamically assess systolic and diastolic 
configurations of the heart. It also helps to 
distinguish the acute coronary syndrome from 
myocarditis. The coronary angiography 
enables to eliminate the coronary artery 
stenosis in myocarditis. 
Speckle tracking echocardiographic 
examination has recently been a useful 
technique in diagnosing patients with acute 
myocarditis. A recent study by Crawfold 
(2009, pp. 179-185), demonstrated that they 
left ventricle strain and strain rate may be 
useful measurements for diagnosis of 
suspected myocarditis patients, even those 
with the preserved left ventricle ejection 
fraction (LVEF). In addition, speckle tracking 
is useful for predicting deterioration and 
overall event-free survival. In general, strain 
rate and global strain values were decreased 
in myocarditis patients when compared with 
healthy individuals. 
There is also an increased activity of cardio-
specific enzymes. However, unlike the 
infarction state the indicator of the troponin’s 
first analysis results does not change.  
Troponins have high specificity and low 
sensitivity. Moreover, troponin T and I are 
elevated more frequently than creatine kinase 
myocardial band fraction, and higher levels of 
troponin T have been shown to be of 
prognostic value. Sedimentation and C-
reactive protein may indicate clinical 
progression and response to treatment, but 
normal values do not exclude an acute 
myocardial inflammatory process, however, 
their specificity is low for myocarditis. The 
relation of new inflammatory cytokines, TNF-
alpha, serum soluble FAS are increased. 
Sheppard et al. indicated that tumor necrosis 
factor receptor-1 (TNFR-1) expression cause 
excessive apoptosis in myocarditis and 
constitute as a factor of poor prognosis. 
A shift to the left in leukoformula, 
leukocytosis, an increase in ESR, increased 
levels of C-reactive protein and  
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immunoglobulins, as well as 
thrombocytopenia (in case of viral affection) 
are also noted. 
Moreover, it should be noted that 
autoantibodies to various cardiac and muscle-
specific autoantigens are found in myocarditis 
and in the dilatation cardiomyopathy patients. 
Evolving molecular technologies have led to 
the characterization of miRNA profiles 
among acute, chronic, and fulminant 
myocarditis, including a relationship to the 
severity of myocardial damage. For example, 
miR-208b and miR-499 are up-regulated 
upon myocardial damage and can be detected 
in plasma of the myocarditis patients. 
Furthermore, according to the Fung et al 
(2016, pp. 496-514) although miR-208b and 
miR-499 are only observed in the fulminant 
myocarditis, other miRNAs demonstrated to 
be altered in acute myocarditis patients 
including miR-155, miR-21, miR-146b, miR-
511, and miR-212. Currently, no miRNAs 
have been found to be specific for the patients 
with chronic myocarditis. The altered 
expression of specific miRNAs during the 
pathological progression of myocarditis 
makes miRNAs interesting further targets for 
treating and diagnosing suspected myocarditis 
patients with greater accuracy. 
For the histological confirmation of the 
diagnosis of myocarditis the endomyocardial 
biopsy should be performed. When viewing a 
biopsy, myocarditis is being diagnosed 
according to the Dallas criteria. 
It is considered to be necessary and sufficient 
to detect two morphological signs in the 
biopsy specimen: inflammatory cell 
infiltration and necrosis or alteration of 
cardiomyocytes. 
If the inflammatory infiltrations are detected 
in biopsy specimens, but there are no signs of 
damage and / or cardiomyocytonecrosis, then 
the diagnosis is doubtful (although at the 
same time it is quite likely). The absence of 
inflammation in biopsy specimens is a good 
reason for the negative diagnostic conclusion. 
Moreover, in case of viral infections in biopsy 
specimens the lymphocytes prevail, in case of 
the bacterial ones - neutrophils do, and in case 
of allergic myocardites - eosinophils do. The 
giant cell infiltration is peculiar to 
myocarditis characterized by the extremely 
severe course, the rapid progression and the 
inevitable occurrence of the fatal outcome. 
Endomyocardial biopsy should be considered 
in the patients with an acute deterioration of 
cardiac function of unknown etiology who are 
unresponsive to medical therapy.  
It should be noted that endomyocardial biopsy 
up to date is the gold diagnosis of 
myocarditis, especially the myocarditis of 
viral etiology. 
X-ray examination shows characteristic signs 
of cardiomegaly, which are: 
- an increase in the lateral size of the heart, up 
to 15.5 cm in men and 14.5 cm in women, 
- an increase in the cardiothoracic index (the 
ratio of the transverse size of the shadow of 
the heart to the internal transverse size of the 
chest) to 50 or more. 
In the majority of the patients with acute 
myocarditis, the radiological characters of the  
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heart chambers’ dilatation on the background 
of effective treatment are significantly 
reduced or even  disappeared. 
Myocardial scintigraphy with 
67
Ga and 
99
Tc 
pyrophosphate in about half of the cases of 
myocarditis allows visualization of areas of 
inflammation and necrosis of the heart 
muscle, thus confirming the diagnosis of 
myocarditis. 
An even greater sensitivity, reaching 100%, is 
possible to attain by the myocardial 
scintigraphy with introduction of the 
monoclonal antibodies to actomyosin labeled 
with 
111
In. 
Cardiovascular magnetic resonance imaging 
(CMRI) provides non-invasive tissue 
characterisation of the myocardium and can 
support the diagnosis of myocarditis. The 
timing of CMRI in suspected myocarditis will 
depend upon local availability and expertise, 
but it is reasonable to first perform CMRI in 
clinically stable patients, prior to 
endomyocardial biopsy. 
CMRI findings consistent with myocarditis 
should be based on the Lake-Louise criteria. 
• Making diagnosis 
The myocarditis diagnosis is made according 
to the recommendations of the NYHA (New 
York Heart Association) in the presence of 
two or more large signs or with one large and 
two small ones. 
1. Large signs include: 
- cardiomegaly heart failure,  
- cardiogenic shock,  
- Morgagni-Adams-Stokes syndrome,  
- ECG abnormalities including rhythm and 
conduction disturbances; increased activity 
and level of cardio-specific enzymes (CPK, 
MB-CPK, LDH, LDG1, LDG2) and 
troponins. 
2. Small signs include: 
- laboratory confirmation of the experienced 
infection (for example, high titers of anti-
inflammatory antibodies), weakening of the 
first tone, the protodiastolic gallop rhythm. 
It is also worth noting that an important 
diagnostic feature is the presence of  
 
 
inflammatory syndrome signs, which include 
the low-grade fever, the increased ESR, 
leukocytosis, fibrinogenemia, increased level 
of C-reactive protein, etc.  
It should be noted also that there are definite 
host related factors which may be responsible 
for myocarditis. These include genetic 
factors, vitamin deficiency (e.g. Vitamin C, 
D, E) and mineral deficiency (e.g. selenium). 
 
 • Treatment 
In mild cases of the disease, therapy is not 
needed and myocarditis resolves on its own. 
In more severe cases, a support for the cardiac 
function is necessary prior to the 
inflammation subsides completely. To reduce 
the burden on the patient's heart they are 
hospitalized or got recommendations to limit 
physical activity. 
Medical preparations and devices for the 
myocarditis treatment include: 
1. Antibiotics against the bacterial infection - 
azithromycin, ceftriaxone, tetracycline etc; 
2. Antiviral drugs in case of the viral infection 
- for example, valaciclovir against disease 
accosted with the Herpes virus, ganciclovir 
against Cytomegalovirus, highly active 
multicomponent anti-retroviral therapy (e.g. 
dolutegravir+tenofovir+emtricitabine) against 
the Human Immunodeficiency Virus etc; 
3. Non-steroidal anti-inflammatory drugs 
(NSAIDSs) - aspirin, ibuprofen, paracetamol 
etc; 
4. Antiarrhythmic drugs - in case of 
arrhythmia types, for example, cordarone 
against atrial fibrillation etc; 
5. Anticoagulants that affect blood clotting to 
avoid the blood clots formation; 
6. High dose of intravenous immunoglobulin, 
for example, staphylococcal antifagin, also  
now like “vaccinum staphylococcum 
therapeuticum” against staphylococcal sepsis. 
If the pumping function of the heart is 
impaired the doctor recommends medications 
that reduce the load on the heart and remove 
excess of fluid. It could be represented by the 
following: 
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1. Angiotensin-converting enzyme 
inhibitors - enalapril, lisinopril, 
ramipril. 
2. Angiotensin II receptor blockers - 
losaratan, valsartan and olmesartan;                                             
Angiotensin-converting enzyme 
inhibitors and angiotensin II receptor 
blockers - significantly reduce 
inflammation, necrosis, and fibrosis of 
the myocardium and improve left 
ventricle function. 
3. Beta-blockers - carvedilol. These 
drugs are prescribed for heart failure 
and irregular or increased heart rate 
(help control arrhythmias). Moreover 
carvedilol shows a cardioprotective 
effect in rats with autoimmune 
myocarditis by suppressing 
inflammatory cytokines and oxidants, 
whereas metoprolol exerts adverse 
effects on CVB3-induced myocarditis 
leading to increased inflammation and 
mortality in the murine model. 
4. Diuretics (diuretics), for example, 
furosemide. 
5. Calcium-channel blockers - for 
example, amlodipine shows a 
protective effect against myocardium 
injury in mice with congestive heart 
failure induced by viral myocarditis 
through blunting of the 
overproduction of nitric monoxide. 
However, administration of calcium-
channel blockers is not generally 
recommended in the management of 
acute heart failure. 
6. Aldosterone antagonist 
(antimineralocorticoid drugs/MCRA) - 
spironolactone were reported to 
reduce the hospital admission for 
worsening heart failure and to increase 
survival of patients with acute or 
chronic heart failure worsening. 
In severe cases the hardware support 
application is needed. It could be represented 
by: 
 
 
 
 
- Intra-aortic balloon counterpulsation. 
This provides pumping out of the 
blood into the aorta by a special pump, 
which thus reduces the burden on the 
heart. 
- Extracorporal membrane oxygenation 
is a way of saturation of blood with 
oxygen and removal of carbon dioxide 
from the blood using the specific 
apparatus. 
- The ventricular assist advice, which 
are specific devices that mechanically 
pump blood from the lower chambers 
of the heart into the systemic 
circulation. Auxiliary pumps are 
needed in case of severe heart failure 
in order to enable the heart recovery 
or to support vital functions while 
awaiting transplantation. 
According to Van Linthout  and Tschope 
(2018, p. 332) the novel treatment options 
include: 
1.   Paquinimod, an immunomodulatory 
compound preventing S100A9 binding to 
the Toll-like receptor-4 (TLR-4) and 
receptor for the end products advanced 
glycation, has been shown to improve 
experimental systemic sclerosis and 
atherosclerosis outcomes.  
2.   Colchicine. Its main working mechanism 
is inhibition of neutrophil chemotaxis, 
adhesion and mobilisation, the reduction 
in superoxide production and inhibition 
of NLRP3 inflammasome activity and 
IL-1betta production. In addition to it, 
colchicine has antifibrotic and 
endothelial-protective features. 
3.   Anakinra. The relevance of the NLRP3 
inflammasome in CVB3 myocarditis, its 
association with a worse prognosis on the 
long term and the fact that IL-1β receptor 
antagonist, Anakinra, is an attractive 
candidate to treat viral myocarditis. 
Although the patients with fulminant 
myocarditis were successfully treated 
with Anakinra, however, the potential of 
Anakinra to treat viral myocarditis has 
not been tested in clinical studies yet. 
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4.   Canakinumab - anti-inflammatory therapy 
targeting the IL-1β pathway with the 
fully human monoclonal antibody against 
IL-1β canakinumab led to a significantly 
lower rate of recurrent cardiovascular 
events than placebo, independent of lipid 
level lowering in patient with myocardial 
infarction and high-sensitivity C-reactive 
protein level (>2mg/l). 
5.   Mesenchymal stromal cells or MSCs are 
well known for their cardioprotective and 
immunomodulatory properties. MSCs 
reduce the CVB3-infected apoptosis and 
consequent viral progeny release. 
6.    Regulatory T cell. It’s a subpopulation of 
CD4+ cell, which play a pivotal role in 
the induction and maintenance of 
immune homeostasis and tolerance in 
setting of viral myocarditis. 
- Immunosuppressive therapy: 
Specific types of myocarditis based on 
autoimmunity are treated with 
immunosuppression, for example, in the 
patients with giant cell myocarditis or 
cardiac sarcoidosis. In case of giant cell 
myocarditis, combined treatment with 
immunosuppressant’s (cyclosporine and 
corticosteroids with or without  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
azathioprine or muromonab  CDs) may 
improve the poor prognosis, and yield a 
median survival time of 12 months 
compared with 3 months for untreated 
affected patients. 
Nevertheless, a minority of patients 
require mechanical circulatory support or 
heart transplantation within a year. 
Withdrawal of immunosuppression can 
result in recurrent and sometimes fatal 
giant cell myocarditis. In case of cardiac 
sarcoidosis, early immunosuppressive 
therapy with high dose of corticosteroids 
has been associated with improved 
cardiac function. The prognosis of 
patients with treatment is variable, with a 
5 year survival ranging from 60% to 
90%. It should be noted that 
immunosuppression against the viral 
myocarditis is not recommended. 
 
- Vaccination: 
Since viruses remain the most common cause 
of myocarditis, it may be possible to carry out 
targeted vaccination in the future. Patients at 
risk will be vaccinated against the most 
typical etiological agents, thus it will be 
Scheme 1: Proposed diagnostic and therapeutic algorithm of the patients with suspected myocarditis according 
with Kindermann et al (2012, pp. 781-782). 
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possible to avoid the development of the 
disease. According to Abgaryan, Mxeyan, 
Zalinyan (2016, pp. 567-568), development of 
endocardial fibroblastosis which is fraught by 
dilated cardiomyopathy in children could be 
ceased through implementation of the mumps 
vaccination program. 
 
Prognosis and Outcome 
The prognosis of patients with myocarditis 
depends on clinical presentation, different 
clinical parameters, and endomyocardial 
biopsy findings. The patients with acute 
myocarditis and preserved left ventricular 
ejection fraction have a good prognosis with a 
high rate of spontaneous improvement 
without sequel. At presentation, the patients 
with fulminant viral myocarditis and 
hemodynamic compromise have an excellent 
long-term prognosis and are more likely to 
experience complete recovery than patients 
with acute myocarditis if aggressive 
pharmacological and/or mechanical 
circulatory support is initiated early, during 
the fulminant phase. In patients with cardiac 
sarcoidosis, prognosis depends apparently on 
an early initiated treatment 
(immunosuppressive therapy or heart 
transplantation). 
A risk stratification approach based on biopsy 
results, clinical findings and drug treatment 
demonstrated that patients in NYHA 
functional class III to IV with positive 
immunohistology and without beta-blocker 
therapy have the poorest prognosis with a 5-
year transplantation free survival rate only in 
39% percent of cases. 
 
Conclusion 
Myocarditis is a unique model for the 
affection and recovery process study taking 
place in the organism. The outcome is 
critically dependent on the etiological agents’ 
virulence, the host-organisms immune system 
capability to realize the corresponding 
response and remove the impaired locus with 
maximal effectiveness. In the future, 
probably, the genetics risk factors 
preconditioning the myocarditis phenotype 
development, as well as its potential 
interaction with the environmental factors is 
being determined. In this respect it is 
approximately true to reveal the patients who 
try to overcome the disease, as well as those, 
who are in the high risk zone considering the 
long-term consequences development 
possibility. 
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